Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19 False Advertising Wasn't Any Falser Than During Other Public Health Crises; The Internet Was The Difference Maker

Executive Summary

The types of unsupported claims made during the COVID-19 pandemic have not been so different from those seen before when the US faced public health emergencies. But this time advertisers' digital capabilities turned up the volume on false and unsubstantiated claims about COVID cures and the like, says Rich Cleland, FTC Consumer Protection Bureau attorney.

You may also be interested in...



Michigan Firm’s Nasal Spray Neither A COVID-19 Treatment Nor For Nasal Use

CofixRx and Sensory Cloud are latest OTC nasal spray marketers FDA warned about fraudulent COVID-19 claims. While the others’ violations were limited to violative claims, CofixRx also warned the active ingredient in its spray is limited to topical use.

Xlear Admits Referencing Research, Avers Studies Support Saline Nasal Spray’s COVID-19 Efficacy

Firm responds to a complaint DoJ filed for FTC. Founder and president Nathan Jones continues criticism that FTC is attempting to silence research-backed advertising for alternatives to pharmaceuticals public health agencies promote for preventing or treating COVID-19.

COVID-19 False Advertising Symptoms In US Exceed FTC’s Prognosis For Number, Variety

FTC Division of Advertising Practices anticipated surge of false ads for consumer health products related to COVID-19 but it didn’t expect quite the number as well as the variety of bogus claims it’s found, says Assistant Director Richard Cleland.

Topics

UsernamePublicRestriction

Register

MT145331

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel